ONC-104

ONC-104 is a preclinical-stage therapeutic candidate being developed by OncoC4 for the treatment of solid tumors. As of early 2024, the specific molecular target and modality of ONC-104 have not been officially disclosed in the company's public pipeline, although it is categorized as a next-generation immunotherapy. The program is part of OncoC4's broader strategy to target the CD24-Siglec innate immune checkpoint pathway, a signaling axis that plays a critical role in immune evasion by tumors. OncoC4 leverages its proprietary pH-sensitive antibody platform to develop assets like ONC-104, aiming to achieve superior efficacy and safety compared to existing checkpoint inhibitors. The drug is currently undergoing preclinical evaluation to support potential future clinical development.